Paul DaSilva‐Jardine
Publications by Year
Research Areas
Estrogen and related hormone effects, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → An EP2 receptor-selective prostaglandin E2agonist induces bone healing(2003)185 cited
- → Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models(1998)157 cited
- → Lysosomal Cholesterol Hydrolysis Couples Efferocytosis to Anti-Inflammatory Oxysterol Production(2018)130 cited
- → Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus(2011)115 cited
- → A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels(2017)111 cited
- → Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1(2011)102 cited
- → Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics(2003)94 cited
- → Selective Activation of AMPK β1-Containing Isoforms Improves Kidney Function in a Rat Model of Diabetic Nephropathy(2017)80 cited
- → Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus(2011)68 cited
- → Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist(2008)62 cited